SCHEMBL242556

SCHEMBL242556

C[C@H](Nc1ccc(O)c(O)c1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.43
GAA P10253 4/20 0.43
RECQL P46063 2/20 0.43
DBH P09172 1/20 0.43
TDP1 Q9NUW8 5/20 0.42
ALOX15 P16050 4/20 0.42
HSD17B10 Q99714 4/20 0.42
HIF1A Q16665 3/20 0.42
PTGS2 P35354 2/20 0.42
USP2 O75604 1/20 0.42
EGFR P00533 1/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
PTGS1 P23219 1/20 0.42
HTR2A P28223 1/20 0.42
SLC7A5 Q01650 1/20 0.42
TOP1 P11387 1/20 0.42
ERCC1 P07992 2/20 0.41
ERCC4 Q92889 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16269615 1.00 KDM4E (0.43) KDM4EGAARECQLDBHTDP1
SCHEMBL4873009 1.00 KDM4E (0.43) KDM4EGAARECQLDBHTDP1
SCHEMBL29715211 1.00 KDM4E (0.43) KDM4EGAARECQLDBHTDP1
SCHEMBL242555 1.00 KDM4E (0.43) KDM4EGAARECQLDBHTDP1
Methane SCHEMBL10504286 0.98 KDM4E (0.42) KDM4EGAARECQLDBHTDP1
SCHEMBL8845474 0.87 KDM5A (0.38) KDM4EGAARECQLDBHTDP1
SCHEMBL28970772 0.84 CA2 (0.39) KDM4EGAARECQLTDP1ALOX15
SCHEMBL2745069 0.84 KMT2A (0.50) KDM4EGAATDP1HSD17B10MAPT
SCHEMBL27486347 0.84 MAPT (0.49) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL1226636 0.84 KDM4C (0.50) KDM4ETDP1HSD17B10PTGS2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260077099-A1 Methods of Treating an Eye Disorder UNIVERSITEIT ANTWERPEN (BE) 2026-03-19 US claimed
US-12410083-B2 Microbe-based systems, compositions, and methods thereof UNIVERSITY OF WASHINGTON (US) 2025-09-09 US claimed
EP-4531944-A1 METHODS OF TREATING AN EYE DISORDER Universiteit Antwerpen (BE) 2025-04-09 EP claimed
CN-116477889-B Diversion tunnel concrete based on coral stone aggregate and construction method thereof 中国水利水电第九工程局有限公司 2024-05-14 CN claimed
WO-2024005225-A1 FILTER COATED WITH FUNCTIONAL POLYPEPTIDE 주식회사 바이오빛 2024-01-04 WO claimed
WO-2023232356-A1 METHODS OF TREATING AN EYE DISORDER UNIVERSITEIT ANTWERPEN (BE) 2023-12-07 WO claimed
CN-116477889-A Diversion tunnel concrete based on coral stone aggregate and construction method thereof 中国水利水电第九工程局有限公司 2023-07-25 CN claimed
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES THE JOHNS HOPKINS UNIVERSTY 2023-07-06 US claimed
WO-2023120782-A1 ADHESIVE CONDUCTIVE HYDROGEL USING RADIATION CROSSLINKING METHOD, METHOD FOR PREPARING SAME, AND ADHESIVE CONDUCTIVE HYDROGEL SHEET USING SAME 서울방사선서비스주식회사 2023-06-29 WO claimed
EP-4157998-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES The Johns Hopkins University (US) 2023-04-05 EP claimed
WO-1997003175-A1 REDOX REAGENT-CONTAINING POST-ETCH RESIDUE CLEANING COMPOSITION OLIN MICROELECTRONIC CHEMICALS, INC. (US) 1997-01-30 WO claimed
US-5472830-A Mixture of polar organic solvent, amine and hydroxy amino acid OCG MICROELECTRONIC MATERIALS, INC. (US) 1995-12-05 US claimed
EP-0678788-A2 Non-corrosive photoresist stripping composition OCG MICROELECTRONIC MATERIALS, INC. (US) 1995-10-25 EP claimed
WO-1995027489-A1 COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-10-19 WO claimed
EP-0516795-A1 USE OF QUISQUALATE-RECEPTOR ANTAGONISTS FOR TREATING PARKINSON'S DISEASE SCHERING AKTIENGESELLSCHAFT (DE) 1992-12-09 EP claimed
WO-1992011012-A1 USE OF QUISQUALATE-RECEPTOR ANTAGONISTS FOR TREATING PARKINSON'S DISEASE SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) 1992-07-09 WO claimed
US-4380646-A Method for the N-acylation of aminocarboxylic acids DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) 1983-04-19 US claimed
US-4005127-A L-Dopa process and intermediates MONSANTO COMPANY (US) 1977-01-25 US claimed
US-3984545-A 3,4-DIHYDROXY-PHENYL-1-ANALINE WITH BENZODIAZEPINES THE UPJOHN COMPANY (US) 1976-10-05 US claimed
US-3941835-A Recovery of L-Dopa from R-dopa containing materials BIO-DERIVATIVES CORPORATION (US) 1976-03-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260077099-A1 Methods of Treating an Eye Disorder CNTN1, AQP4, BDNF KDM4E 636/4885GAA 4481/4885RECQL 2995/4885
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES EPX, EPCAM, ELANE KDM4E 3727/4885GAA 248/4885RECQL 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.